Scarica l'app Stockscreener
62.69
0.71%
0.44
Pre-mercato:
64.58
1.89
+3.01%
Precedente Chiudi:
$62.25
Aprire:
$62.27
Volume 24 ore:
237.65K
Relative Volume:
1.45
Capitalizzazione di mercato:
$693.33M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+10.58%
1M Prestazione:
+15.77%
6M Prestazione:
+123.97%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$62.02
$65.57
Intervallo di 1 settimana:
$56.55
$65.57
Portata 52W:
$11.17
$65.57
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
125 STRAFFORD AVE, WAYNE
Confronta PVLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
62.69 | 688.46M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Can Palvella Therapeutics Inc. (PI6) stock attract ESG investmentsWeekly Profit Analysis & Free Expert Approved Momentum Trade Ideas - newser.com
Will Palvella Therapeutics Inc. bounce back from current supportWeekly Trend Report & Safe Swing Trade Setups - newser.com
Can Palvella Therapeutics Inc. (PI6) stock deliver consistent EPS growthSwing Trade & Technical Pattern Based Buy Signals - newser.com
Tick level data insight on Palvella Therapeutics Inc. volatilityEarnings Beat & Weekly High Potential Stock Alerts - newser.com
How to interpret RSI for Palvella Therapeutics Inc. stockJuly 2025 Selloffs & Safe Capital Growth Tips - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High Following Analyst Upgrade - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week High After Analyst Upgrade - MarketBeat
Published on: 2025-09-29 15:57:39 - newser.com
Will Palvella Therapeutics Inc. (PI6) stock beat Nasdaq index returnsJuly 2025 Earnings & High Win Rate Trade Alerts - newser.com
How to build a custom watchlist for Palvella Therapeutics Inc.Trade Analysis Report & Risk Managed Trade Strategies - newser.com
Published on: 2025-09-29 09:58:44 - newser.com
Palvella Expands QTORIN Rapamycin Program Into Rare Angiokeratomas - MyChesCo
Published on: 2025-09-29 07:36:24 - newser.com
Equities Analysts Offer Predictions for PVLA FY2028 Earnings - Defense World
Published on: 2025-09-28 21:37:00 - newser.com
Palvella Therapeutics Inc Stock Analysis and ForecastVolume Spike Alerts & Budget Friendly Portfolio - earlytimes.in
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Cutaneous Venous Malformations - MyChesCo
What analysts say about Palvella Therapeutics Inc stockHealthcare Stock Analysis & Minimal Investment Capital - earlytimes.in
Palvella Expands QTORIN Gel Program for Rare Disease - MSN
Best data tools to analyze Palvella Therapeutics Inc. stockPortfolio Return Report & Real-Time Market Sentiment Alerts - newser.com
Published on: 2025-09-27 05:34:37 - newser.com
Applying big data sentiment scoring on Palvella Therapeutics Inc.Analyst Downgrade & Long Hold Capital Preservation Tips - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $73.00 at Chardan Capital - MarketBeat
Chardan Capital Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Chardan Raises Price Target on Palvella Therapeutics to $73 From $60, Keeps Buy Rating - MarketScreener
Goldman Sachs Group Inc. Makes New $533,000 Investment in Palvella Therapeutics, Inc. $PVLA - MarketBeat
HC Wainwright & Co. Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Palvella Therapeutics stock price target raised to $70 at Jones Trading - Investing.com UK
Palvella to develop therapy for rare skin condition with no approved treatments By Investing.com - Investing.com South Africa
Stifel Maintains 'Buy' Rating and Raises Price Target for PVLA t - GuruFocus
Stifel Nicolaus Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $80.00 - MarketBeat
Palvella Therapeutics stock price target raised to $80 by Stifel on new skin treatment - Investing.com Canada
Palvella Therapeutics stock price target raised to $90 from $85 at Oppenheimer - Investing.com UK
Palvella to develop therapy for rare skin condition with no approved treatments - Investing.com Canada
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Non sono disponibili dati finanziari per Palvella Therapeutics Inc (PVLA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):